

The RESPIMAT inhaler was awarded the Arthritis Society's Ease-of-Use Commendation



The Arthritis Society's Ease-of-Use Commendation recognizes products, like the RESPIMAT inhaler, that have been independently tested for easy use and handling for people living with arthritis.

The Arthritis Society does not determine the therapeutic value of products and the designation is not intended as a general product endorsement.¹

INSPIOLTO RESPIMAT (tiotropium bromide monohydrate and olodaterol hydrochloride) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta₂-adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema.²

The first and only LAMA/LABA delivered by a soft mist inhaler^{3†}



Please consult the product monograph at www.boehringer-ingelheim.ca/sites/ca/files/documents/inspioltorespimatpmen.pdf for conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions and dosing. The product monograph is also available by calling us at 1 (800) 263-5103 Ext. 84633.

† Comparative clinical significance has not been established.

References:

1. Data on file. Boehringer Ingelheim (Canada) Ltd. February 1, 2019. Available at: www.arthritis.ca/get-involved/ways-to-give/corporate-giving/ease-of-use.
2. INSPIOLTO™ RESPIMAT® Product Monograph. Boehringer Ingelheim (Canada) Ltd. June 24, 2019.
3. Data on file. Boehringer Ingelheim (Canada) Ltd. August 30, 2018.



**Boehringer
Ingelheim**

INSPIOLTO™ is a trademark and RESPIMAT® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.
© 2019 Boehringer Ingelheim (Canada) Ltd.
All rights reserved. INS-CA-100760-E



INSPIOLTO™
RESPIMAT®
TIOTRIPIUM & OLODATEROL